Zura Bio Limited ( (ZURA) ) has released its Q2 earnings. Here is a breakdown of the information Zura Bio Limited presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zura Bio Limited is a clinical-stage immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. In the second quarter of 2025, Zura Bio reported significant progress in its clinical programs, including the initiation of a global Phase 2 study for tibulizumab in hidradenitis suppurativa and continued advancement in systemic sclerosis. The company also strengthened its leadership team with new appointments to support its growth. Financially, Zura Bio reported $154.5 million in cash and cash equivalents, expected to fund operations through 2027, despite a net loss of $16 million for the quarter. Research and development expenses increased due to ongoing clinical studies, while general and administrative expenses rose due to organizational expansion. Looking ahead, Zura Bio remains committed to advancing its clinical programs and strategic goals, with anticipated data readouts in 2026 expected to guide future development decisions.